Navin Fluorine International Limited Board of Directors of the Company at their meeting held December 21, 2017, has approved a capital expenditure of INR 1,150 million towards creating additional cGMP capacity and associated infrastructure at its Dewas facilities. The expanded capacity will be utilized for the Company's expanding contract manufacturing activity for the value added complex chemicals and fluoro intermediates manufactured for innovator pharma companies across the globe. The Investment in expansion of the capacity is based on customer enquiries and discussions and in anticipation of future research pipeline of innovators. The new capacity addition will be similar to the Company's existing multi product plant configuration with multistage batch and products processing capabilities. The New capacity is expected to come on stream by June 2019. The capital investment of INR 1,150 million will be funded through a combination of internal accruals and debt.